Skip to main content

Table 2 Disease events and deaths prevented with the two vaccination strategies associated with cervical screening

From: Assessing the epidemiological impact on cervical cancer of switching from 4-valent to 9-valent HPV vaccine within a gender-neutral vaccination programme in Switzerland

HPV 16/18/31/33/45/52/58 related disease incidence cases and deathsYears since start of vaccination programme
2550100
CIN1 cases- females
 4vHPV vs screening (nb of events avoided)312511,57931,382
 9vHPV vs screening (nb of events avoided)427816,14644,084
 9vHPV vs 4vHPV (nb of events avoided)1153456712,702
 Cumulative incidence decrease, 9vHPV vs 4vHPV (%)10.427.149.8
CIN2 cases- females
 4vHPV vs screening (nb of events avoided)394814,85240,551
 9vHPV vs screening (nb of events avoided)532120,25455,552
 9vHPV vs 4vHPV (nb of events avoided)1373540115,000
 Cumulative incidence decrease, 9vHPV vs 4vHPV (%)9.825.647.8
CIN3 cases- females
 4vHPV vs screening (nb of events avoided)423218,22754,031
 9vHPV vs screening (nb of events avoided)522422,78967,893
 9vHPV vs 4vHPV (nb of events avoided)991456213,862
 Cumulative incidence decrease, 9vHPV vs 4vHPV (%)5.216.135.5
Cervical cancer cases- females
 4vHPV vs screening (nb of events avoided)242231610,414
 9vHPV vs screening (nb of events avoided)305296113,394
 9vHPV vs 4vHPV (nb of events avoided)636442979
 Cumulative incidence decrease, 9vHPV vs 4vHPV (%)1.27.124.2
Cervical cancer deaths- females
 4vHPV vs screening (nb of deaths avoided)163992554
 9vHPV vs screening (nb of deaths avoided)205123295
 9vHPV vs 4vHPV (nb of events avoided)4113741
 Cumulative incidence decrease, 9vHPV vs 4vHPV (%)0.34.119.7
\